Transarterial Chemoembolization for Hepatobiliary Cancer: History, Background and Role
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Surgery".
Deadline for manuscript submissions: closed (1 January 2024) | Viewed by 191
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and its incidence is still on the rise. Currently, this malignant disease is the sixth most frequent cancer and represents one of the leading causes of cancer-related mortality in men. It is expected that after 2025 more than 1 million cases will be diagnosed annually, demonstrating that HCC remains uncontrollable diseases in health-care systems worldwide.
Transarterial chemoembolization (TACE) is well established, first-line treatment modality for intermediate stage HCC patients within the Barcelona Clinic Liver Cancer (BCLC) staging system. Moreover, according to 2014 TACE algorithm presented by Raoul and co-workers this treatment modality can be used for patients at any HCC stage. The same is confirmed by recently published 2022 BCLC update incorporating the model of treatment stage migration.
The pertinence of TACE treatment is well affirmed by the BRIDGE study that was a multiregional, large-scale cohort study aimed at presenting the real-life treatment of HCC patients. The study results indicated that across all stages TACE was the most frequent treatment modality in North America, Europe, China and South Korea.
In this special issue, we present the history, background and role of TACE within the complex frame of multimodal treatment approach in the management of hepatocellular carcinoma.
Prof. Dr. Danijel A. Galun
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transarterial chemoembolization (TACE)
- hepatobiliary cancer
- hepatocellular carcinoma
- liver cancer
- tumor ablation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
